Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 1, 2009, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug
ScheduleMethcathinone (1237)
IN-Ethylamphetamine (1475)
IN,N-Dimethylamphetamine (1480)
I4-Methylaminorex (cis isomer) (1590)
IAlpha-ethyltryptamine (7249)
ILysergic acid diethylamide (7315)
I2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
ITetrahydrocannabinols (7370)
IMescaline (7381)
I4-Bromo-2,5-dimethoxyamphetamine (7391)
I4-Bromo-2,5-dimethoxyphenethylamine (7392)
I4-Methyl-2,5-dimethoxyamphetamine (7395)
I2,5-Dimethoxyamphetamine (7396)
I2,5-Dimethoxy-4-ethylamphetamine (7399)
I3,4-Methylenedioxyamphetamine (7400)
IN-Hydroxy-3,4-methylenedioxyamphetamine (7402)
I3,4-Methylenedioxy-N-ethylamphetamine (7404)
I3,4-Methylenedioxymethamphetamine (MDMA) (7405)
I4-Methoxyamphetamine (7411)
IAlpha-methyltryptamine (7432)
IBufotenine (7433)
IDiethyltryptamine (7434)
IDimethyltryptamine (7435)
IPsilocybin (7437)
IPsilocyn (7438)
I5-Methoxy-N,N-diisopropyltryptamine (7439)
IN-Ethyl-1-phenylcyclohexylamine (7455)
I1-(1-Phenylcyclohexyl)pyrrolidine (7458)
I1-Phenylcyclohexylamine (7460)
I1-[1-(2-Thienyl)cyclohexyl]piperidine (7470)
INormorphine (9313)
IMethamphetamine (1105)
IIPhencyclidine (7471)
IIPhenylacetone (8501)
II1-Piperidinocyclohexanecarbonitrile (8603)
IICocaine (9041)
IICodeine (9050)
IIDihydrocodeine (9120)
IIDihydromorphine (9145)
IIEcgonine (9180)
IIMeperidine intermediate-B (9233)
IINoroxymorphone (9668)
II
 The company plans to manufacture high purity drug standards used for analytical application only in clinical, toxicological, and forensic laboratories. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, 
                    **Federal Register**
                     Representative (ODL), 8701 Morrissette Drive, 
                    ( print page 46233)
                    Springfield, Virginia 22152; and must be filed no later than November 9, 2009. Dated: August 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. E9-21525 Filed 9-4-09; 8:45 am] BILLING CODE 4410-09-P